3rd World Congress on
Bioavailability & Bioequivalence:
Pharmaceutical R&D Summit-2012

March 26-28, 2012, Marriott Hotel & Convention Centre, Hyderabad, India

BABE-2012 Report

Bioavailability and/or Bioequivalence (BABE) studies play an important role during the process of drug development and it applies to both new drugs as well as to their generic counterparts. BA/BE studies are also vital for the post approval process due to changes done in manufacturing of drugs. Realizing the importance of BA/BE in modern day world, The 3rd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R&D Summit-2012 was organized by OMICS Group during March 26-28, 2012 at Marriott Hotel & Convention Centre, Hyderabad, India.

The response to 3rd World Congress on Bioavailability & Bioequivalence was huge and was attended by about 600 delegates representing 30 countries from different corners of the world. BABE-2012 was comprised of 48 sessions designed to offer comprehensive sessions that addressed current issues in Bioavailability & Bioequivalence research. There were about 25 invited lectures delivered by both Honorable Guests and members of the keynote forum. Honorable Guests list included R. P. Thakur IPS, Director General-Drugs Control Administration, Andhra Pradesh, India, A.Chandra Sekhar Rao, Deputy Drugs Controller-Central Drugs Standard Control Organization, Andhra Pradesh, India, K. Praveen Kumar Vice President, Marketing and Investment Promotion, APIIC, Andhra Pradesh, India; Dr. Luigi Silvestro, Co-founder, 3S-Pharmacological Consultation & Research GmbH, Germany; Dr. Gregory Russell-Jones, Director, Mentor Pharmaceutical Consulting, Australia; Dr. Reddy's Laboratories, India; Dr. A.T. Bapuji, Senior Vice President, Aurobindo Pharma, India; and Dr. Gedela S. Babu, Director of OMICS Group Inc., USA.

The theme of this congress was on "Novel Approaches in Drug Development by Comparing Bioavailability and Bioequivalence Studies". Based on this, speaker's discussions included many recommendations, among those the following are the key recommendations.

  • Studies on Bioavailability (BA) and Bioequivalence (BE) play a key role in providing information to ensure the availability of safe and effective medicine to the patients
  • There is a need to make efforts at the national and international levels to determine appropriate procedures for BA and BE. Regulatory guidelines in India need to be identified for the conduct of bioavailability and bioequivalence studies by the respective regulatory authorities.
  • BA and BE gained much interest during the last few decades after it became known that marketed products having the same amounts of the drug may exhibit marked differences in their therapeutic responses.

The hugely successful event was sponsored by Drug Monitoring Research Institute, Absciex, Agilent Technologies, and Thermo Fisher Scientific (India) Pvt. Ltd. The event received wide coverage in Pharma Times and in CR Networks.

At the end of the conference participants too accepted that the prospects of BA and BE are good for achieving the Strategy's goal for " Novel Drug development " in the region, like India but effort is still needed to enhance the development and the conferences like these organized by OMICS Group really enhances the path for Novel Drug Development.

Expert Presentations
Luigi Silvestro

3S-Pharmacological Consultation & Research GmbH,
Gregory Russell-Jones

Mentor Pharmaceutical Consulting,
Debabrata Mukhopadhyay

Mayo Clinic College of Medicine,
Simona Rizea Savu

3S-Pharmacological Consultation & Research GmbH,
Sharma S. Prabhakar

Texas Tech University Health Sciences Center,

Shengjun Zhang

Frontage China Clinical Research Center,
Gopal Vaidyanathan

Waters India Pvt. Ltd.,

Abbas Mohammad Ghawi

International Islamic University Malaysia,
Naser Rezk

King Abdullah International Medical Research Center,
Kingdom of Saudi Arabia
Shivanand P. Puthli

Panacea Biotec Ltd.,

Yahdiana Harahap

University of Indonesia,

Sinerik N. Ayrapetyan
UNESCO Chair-Life Sciences International Postgraduate Educational Center,
S. Ravisankar

GVK Biosciences Pvt Ltd,

Khalid M Alkharfy

King Saud University,

Saudi Arabia
Innocent Omalu

Federal University of Technology,

Sangram Patnaik

Thermo Fisher Scientific Pvt. Ltd.,
S.V.Krishna Prasad

Cito Healthcare Pvt. Ltd,

A.T. Bapuji

Senior Vice President, Aurobindo Pharma,

D.Vijaya Bharathi

Dr.Reddy's Laboratories Ltd,

Chinmoy Ghosh

Cadila Pharmaceuticals Limited,

Shailendra K. Saxena

Centre for Cellular and Molecular Biology,

Follow us on
Conference Secretariat: BABE-2012, OMICS Group Conferences
5716 Corsa Ave, Suite 110, Westlake, Los Angeles, CA 91362-7354, USA
Tel: +1-650-268-9744, Fax: +1-650-618-1414
Toll free: 1-800-216-6499(USA & Canada),
1-800-651-097(Australia), 0805-080048(Europe)
Operated by: Editors - Journal of Bioequivalence & Bioavailability, Journal of Bioanalysis & Biomedicine
and Pharmaceutica Analytica Acta
The Organizers reserve the rights to make changes and adjustment to the information in this website
© Copyright 2008-2012 OMICS Group - All rights reserved